To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

CTLA4-Ig but not anti-TNF… - University of Gothenburg, Sweden Till startsida
To content Read more about how we use cookies on

CTLA4-Ig but not anti-TNF therapy promotes staphylococcal septic arthritis in mice.

Journal article
Authors Abukar Ali
Amanda Welin
Jan-Christoph Schwarze
Mattias Svensson
Manli Na
Anders Jarneborn
Malin Magnusson
Majd Mohammad
Jakub Kwiecinski
Elisabet Josefsson
Johan Bylund
Rille Pullerits
Tao Jin
Published in The Journal of infectious diseases
Volume 212
Issue 8
Pages 1308-1316
ISSN 1537-6613
Publication year 2015
Published at Institute of Medicine, Department of Rheumatology and Inflammation Research
Institute of Medicine
Institute of Odontology, Section 3
Pages 1308-1316
Language en
Keywords Staphylococcus aureus, septic arthritis, mouse, abatacept, etanercept
Subject categories Basic Medicine, Immunobiology, Clinical Medicine, Infectious Medicine


 The development of biologics has greatly increased the quality of life as well as the life expectancy of many RA patients. However, a large number of these patients are at an increased risk of developing serious infections. The aim of this study was to examine differential effects of anti-TNF versus CTLA4-Ig treatment on both immunological response and host defense in a murine model of septic arthritis.

Page Manager: Webmaster|Last update: 9/11/2012

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?